Rosemont enhances its ability to develop products for global market with acquisition of Sabal Therapeutics and its affiliates Metacel Pharmaceuticals, Palmetto Pharmaceuticals, Athena Bioscience and Sarras Health.
Leeds, UK – (July 2024) – Rosemont Pharmaceuticals Ltd. (“Rosemont”), a leading developer, manufacturer, and distributor of liquid medicines for over 50 years, has acquired Sabal Therapeutics and its affiliates Metacel Pharmaceuticals, Palmetto Pharmaceuticals, Athena Bioscience and Sarras Health, a group of privately owned specialty pharmaceutical companies and distributors of prescription, liquid medicines, based in Watkinsville, Georgia, USA.
This acquisition further enhances Rosemont’s ability to serve patients with swallowing difficulties across the USA. Previously, Rosemont has developed, registered and supplied medicines to the US market via distribution partners. This acquisition now provides the company with the ability to supply branded and generic medicines directly into the US market. In addition to the existing portfolio included in this transaction, Rosemont has an extensive pipeline of novel, liquid medicines designed for the US market and patients.
Howard Taylor CEO of Rosemont said“Acquiring Sabal is a key milestone for Rosemont to commercialise our world class medicines to help US patients with swallowing difficulties, building on our platform of high-quality development teams in both the UK and Greece. Our Vice President for the US Market, John Denman, who heads our Rosemont Inc US operations, will be leading this venture and all of us at Rosemont are looking forward to working with the Sabal team.”
Sabal president and CEO Jeff Bryant said, “this fusion of Rosemont and Sabal allows us to greatly expand our vision across therapeutic areas, with the ultimate mission of changing patients’ lives for the better. We are delighted to join the Rosemont team to deliver even greater value to our providers and those in their care.”
For more information, please contact:
Janet Maclean at Janet.Maclean@rosemontpharma.com
About Rosemont Pharmaceutical Ltd.
Rosemont has over 50 years of expertise in the development, manufacture and distribution of oral liquid medicines. Since the release of its first liquid medicine in 1974, Rosemont has continued conducting research, developing and bringing new products to market advocating support for vulnerable patients with swallowing difficulties. As of 2024, Rosemont has a portfolio of over 130 oral liquid medicines across a range of therapeutic areas including over 100 licensed products in 27 international markets.
Learn more at www.rosemontpharma.com
About Sabal Therapeutics
Sabal is a fully integrated pharmaceutical company that has sales and marketing capabilities, with an additional commercial office based in Greenville, South Carolina, to promote its own assets developed by CROs and manufactured by CMOs, commissioned by Sabal. It has the requisite operations, quality, pharmacovigilance and financial management teams, based in Watkinsville, Georgia, and its own 3PL in support of its trade relations and distribution, located in Bogart, Georgia.
Learn more at www.sabaltherapeutics.com
ROS000116, DOP July 2024